About Interius Biotherapeutics
Interius Biotherapeutics is a Healthcare company based in Philadelphia (United States) founded in 2020, and was acquired by Kite Pharma in August 2025. Developer of gene therapies for treating multiple diseases. Interius Biotherapeutics has raised $129.03 million across 4 funding rounds from investors including Pfizer, BrightEdge and Kite Pharma. The company has 25 employees. Interius Biotherapeutics offers products and services including LENTIVECTOR Platform, INT2104, and INT2106. Its focus areas include Life Sciences, Gene Therapy, Diversified and Immunotherapy. Its legal entity is Interius BioTherapeutics, Inc. Its competitors include Moderna, Senti Biosciences and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Interius Biotherapeutics was founded in 2020 in Philadelphia, United States, within the biotherapeutics sector. Gene therapies targeting various diseases are developed through lentiviral pseudotyping to improve efficiency. In-vivo generation of therapeutic cells, such as CAR-T cells for cancers, regulatory T cells for autoimmune conditions, and CD34 hematopoietic stem cells for blood disorders, is focused on by the company. Operations emphasize innovative cell transformation methods.
- Headquarters Philadelphia, United States
- Employees 25
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website interiusbio.com
- Social LinkedIn X
- Acquired by Kite Pharma (Aug 2025)
- Legal Name Interius Biotherapeutics, Inc.
- Total Equity Funding$129.03M (USD)
in 4 rounds
- Latest Funding Round$51.43M (USD), Series A
May 2024
- InvestorsPfizer
& 16 more
- Employee Count25
- Acquired byKite Pharma
(Aug 2025)
Products & Services of Interius Biotherapeutics
Interius Biotherapeutics offers a comprehensive portfolio of products and services, including LENTIVECTOR Platform, INT2104, and INT2106.
System for precise delivery of genetic medicines to treat diseases.
Lentivector-based treatment targeting oncology applications.
Advanced therapeutic for autoimmunity via genetic medicine.
Funding Insights of Interius Biotherapeutics
Interius Biotherapeutics has successfully raised a total of $129.03M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $51.43 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $129.03M
- Total Rounds 4
- Last Round Series A — $51.43M
- First Round $1.6M
(Mar 2020)
- Investors Count 16
All 4 funding rounds of Interius Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $51.43M | Series A | – | – | – |
| Oct 2023 | $21.45M | Debt – Conventional | – | – | – |
| May 2021 | $76M | Series A | – | Fairmount Funds Management, Cormorant Asset Management | |
| Mar 2020 | $1.6M | Seed | – | Tellus BioVentures, Agent Capital | – |
17 investors in total: 17 institutional.
Investors in Interius Biotherapeutics
Interius Biotherapeutics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, BrightEdge and Kite Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Agent Capital is focused on healthcare venture capital investments. | agentcapital.com | Waltham, United States | ||
Investments are directed toward early and growth stage companies. | quancapital.com | Pudong, China | ||
Tellus BioVentures is focused on early-stage biotechnology investments. | tellusbv.com | Miromar Lakes, United States | ||
Healthcare startups are funded by this venture capital firm. | cormorantassetmanagement.tcc.mode | Ponte Vedra, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Health System | 1993 | pennmedicine.org | United States | |
Delivers investment management services with a focus on portfolio construction and risk assessment. | 2016 | fairmountfunds.com | Philadelphia, United States |
Investor details for Interius Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Interius Biotherapeutics
13 people are tracked at Interius Biotherapeutics (5 in leadership, 7 in board & advisors, 1 in team); the tracked headcount is 25.
| Name | Role | Group |
|---|---|---|
Phil Johnson | President & CEO | Leadership |
Bruce Schnepp | Senior Director, Platform Development | Leadership |
Dora Mitchell | SVP, Operations & Chief of Staff | Leadership |
Scott J. Dooley | Director, Intellectual Capital | Leadership |
Philip R. Johnson M.D. | Chief Executive Officer | Leadership |
Bruce Peacock | Founder | Board & advisors |
Tomas Kiselak | Director | Board & advisors |
Lonnie Moulder | Chairman | Board & advisors |
Benjamin Lund | Director | Board & advisors |
Saar Gill | Founder, SAB Chair | Board & advisors |
Richard Peluso | Advisor | Board & advisors |
Mike Betts | Advisor | Board & advisors |
Lovisha Love-Diggs | Finance Controller | Team |
Complete people profiles for Interius Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Interius Biotherapeutics
4 dated milestones of Interius Biotherapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Interius Biotherapeutics is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Series A, of $51.4M.
- Exit Acquired by Kite Pharma.
Competitors of Interius Biotherapeutics
Interius Biotherapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, Senti Biosciences and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Interius Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Interius Biotherapeutics
The website of Interius Biotherapeutics (interiusbio.com) receives about 2K visits a month.
- Monthly visits2K
▼ 29.5% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Interius Biotherapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Interius Biotherapeutics
Complete news archive for Interius Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Interius Biotherapeutics
Interius Biotherapeutics was founded in 2020.
Interius Biotherapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Interius Biotherapeutics is a funded company, having raised a total of $129.03M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.6M, raised on Mar 2020.
Interius Biotherapeutics has 25 employees.
Interius Biotherapeutics was founded in 2020 in Philadelphia, United States, within the biotherapeutics sector. Gene therapies targeting various diseases are developed through lentiviral pseudotyping to improve efficiency. In-vivo generation of therapeutic cells, such as CAR-T cells for cancers, regulatory T cells for autoimmune conditions, and CD34 hematopoietic stem cells for blood disorders, is focused on by the company. Operations emphasize innovative cell transformation methods.
Interius Biotherapeutics's top competitors include Moderna, Forge Biologics and Senti Biosciences.
Interius Biotherapeutics offers LENTIVECTOR Platform, INT2104, and INT2106.
Interius Biotherapeutics has 17 investors. Key investors include Pfizer, BrightEdge, Kite Pharma, Penn Medicine, and RA Capital.
Interius Biotherapeutics operates through Interius Biotherapeutics, Inc..
Yes. Interius Biotherapeutics was acquired by Kite Pharma in August 2025.